Back to top

vaccines: Archive

Zacks Equity Research

Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal

Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.

SNYNegative Net Change PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change

Zacks Equity Research

Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y

Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

MRKPositive Net Change MRNAPositive Net Change LGNDPositive Net Change ANIPNegative Net Change

Zacks Equity Research

GSK Beats Q1 Earnings & Sales Estimates, Ups 2024 Guidance

GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales for the full year.

GSKPositive Net Change JNJPositive Net Change ANIPNegative Net Change VIRNegative Net Change

Zacks Equity Research

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

REGNPositive Net Change PFENegative Net Change NVONegative Net Change AMGNNegative Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect

Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.

MRKPositive Net Change MRNAPositive Net Change SRPTNegative Net Change ARGXNegative Net Change

Zacks Equity Research

AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up

AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.

SNYNegative Net Change AZNNegative Net Change MRKPositive Net Change AMGNNegative Net Change

Zacks Equity Research

GSK Gears Up for Q1 Earnings: Here's What to Expect

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Nucala, Trelegy Ellipta and Shingrix to drive first-quarter sales performance.

GSKPositive Net Change SRPTNegative Net Change CTMXNegative Net Change ARGXNegative Net Change

Zacks Equity Research

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.

GSKPositive Net Change ANIPNegative Net Change ADMAPositive Net Change ENTXNegative Net Change

Zacks Equity Research

Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.

PFENegative Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

MRKPositive Net Change MRNAPositive Net Change ANIPNegative Net Change ADMAPositive Net Change